Close menu




EVOTEC SE INH

Photo credits: pixabay.com

Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

  • Evotec
  • Vidac Pharma
  • Novo Nordisk
  • Drug discovery
  • Biotech
  • Pharma
  • Cancer
  • Oncology
  • Warburg effect
  • Obesity
  • Diabetes
  • Weight-loss pill

Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

Read

Commented by Matthias Schomber on November 9th, 2026 | 05:43 CET

Palantir Shares in Turmoil! Evotec Gains Momentum! Buying Opportunity in Lahontan Gold After the Consolidation!

  • biotech
  • evotec
  • palantir
  • intelligence service
  • ai
  • authorities
  • states
  • gold
  • lahontan
  • lahontan gold
  • gold mine
  • pea
  • gold production

Chip stocks are posting double-digit percentage declines. Investors fear the AI bubble could burst or that growth may no longer continue at the same pace. Corporate spending could be scaled back. Dutch bank ING is offering a portfolio of around USD 500 million in data centre loans for sale. This could indicate an attempt to pass on the risk. Investors are now desperately searching for the real winners of today and tomorrow beyond the broader market crowd. While AI software giant Palantir is also struggling with share price declines, biotech pioneer Evotec is seeking to embark on the painful road to recovery. The commodities sector also offers exciting opportunities, such as Lahontan Gold. Find out in the following article which fundamental data and technical levels really matter now for Palantir, Evotec and Lahontan Gold and where the opportunities for your portfolio may lie!

Read

Commented by André Will-Laudien on November 2nd, 2026 | 05:43 CET

The Biotech breakout: Bayer and Eli Lilly flex their muscles - are Novo Nordisk, Evotec and BioNxt the next winners?

  • BioTech
  • Pharma
  • Active ingredients
  • Oncology
  • Drug developers

That was a week of selling on the NASDAQ! The technology index lost a full 5% in its renewed attempt to exceed the 30,000-point mark. Chip stocks, which had previously performed excellently, came under considerable pressure, followed by subdued figures from Alphabet, Microsoft and, most recently, Intel. The result was hefty double-digit losses; this sector has not seen this much uncertainty in a long time. Things are very different in the biotech sector. At 7,319 points, the underlying NASDAQ Biotech Index only narrowly missed its all-time high of 7,458 points. Leading players such as Bayer and Eli Lilly brought a breath of fresh air to the sector, which could now significantly outperform other industries towards the end of the year. We take a closer look at some of the protagonists.

Read

Commented by André Will-Laudien on October 29th, 2026 | 05:39 CET

Life Sciences in Focus as Sector Rotation Takes Shape: Bayer, Vidac Pharma, Eli Lilly, Novo Nordisk and Evotec in 2027

  • BioTech Pharma
  • Drug Development
  • Drug Discovery
  • Cancer Therapy

AI is consolidating, and the Life Sciences sector is firing up its first turbo: Rising healthcare spending, the demographic ageing wave and a veritable wave of innovation are catapulting the industry straight into a multi-year supercycle – and now the major players are reallocating their capital. AI and high-tech have delivered their returns, and now the new outperformers for 2027 are stepping into the spotlight. The catch: after years of heavy losses, most stocks are trading close to their 5-year lows. That will not last! Some companies are already waiting in the wings, with the painful restructuring completed. Leading the way, Novo Nordisk continues its relentless advance as the undisputed flagship of the global obesity and diabetes wave. A genuine hidden gem for return hunters is Vidac Pharma. Through its research into the Warburg effect, the biotech firm is revolutionising cancer therapy and, as a classic high-beta play, adds a dash of spice to opportunity-focused portfolios. The giant Bayer is also back, consistently using the current valuation lull as a major entry opportunity to ignite the next phase of growth with a revamped pipeline. The power quartet is completed by Hamburg-based drug discovery company Evotec, which benefits directly from demand for complex therapies as an indispensable infrastructure and development partner. Those who want to stay ahead in the coming Life Sciences boom need to set the course for their portfolio now!

Read

Commented by Fabian Lorenz on October 23rd, 2026 | 05:38 CEST

Strong News and Buy Recommendations: Vonovia, Evotec and Lahontan Gold

  • precious metals
  • gold
  • silver
  • biotechnology
  • real estate

Strong news from Lahontan Gold. The explorer has published a positive preliminary economic assessment (PEA) for its Santa Fe gold-silver project in Nevada. The after-tax net present value stands at approximately USD 820 million, significantly exceeding the company's current market capitalisation. The company is also working to expand the resource base. While Lahontan Gold shareholders can look forward to the approaching start of gold production, Vonovia shareholders face an uncertain future. The expropriation scenario is weighing on sentiment. Even JPMorgan's assessment that these concerns are exaggerated does little to change the picture. In a worst-case scenario, the German government would intervene. And what about Evotec? The shares have gained more than 10% in recent trading days. The appointment of a new executive at Novo Nordisk could inject fresh momentum into the company.

Read

Commented by Stefan Bode on October 20th, 2026 | 05:31 CEST

Turnaround Opportunities and Share Price Shocks: Almonty Industries, Evotec and PNE Put to the Test

  • Almonty Industries
  • Evotec
  • PNE

Today's commentary deals with an operational turning point, geopolitical realignment and severe setbacks. While a struggling drug discovery company fights to find a bottom with surprising quarterly figures, a Western raw materials producer benefits from a geopolitical break with former monopoly suppliers. Meanwhile, a drastic profit warning in the renewable energy sector plunges investors into a deep crisis of confidence. This market report analyses which technical hurdles now matter and where genuine opportunities lie despite high volatility.

Read

Commented by Fabian Lorenz on October 15th, 2026 | 05:25 CEST

Nel ASA and Evotec Shares Rise! When Will DRC Gold Take Off?

    Evotec shares gained more than 9% yesterday, driven by better-than-expected figures for the first nine months. In an initial reaction, analysts once again recommended buying the stock. Nel ASA has also received positive news in recent days. The Norwegian company secured an order in the United States, while its collaboration with Rheinmetall is also attracting attention. The aim is to jointly develop solutions for local production of low-emission fuels, particularly for the defence sector and critical infrastructure. Could DRC Gold shares be poised for a breakout? The company, led by a German CEO, aims to establish itself in one of Africa's most historic gold-producing regions. It recently reached an important milestone. The aim is to bring the Kebigada deposit, with a historical resource estimate of around 4.1 million ounces of gold, into production as quickly as possible. Further acquisitions are also under consideration.

    Read

    Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST

    Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!

    • Oncology
    • Cancer Therapy
    • Pharma
    • Biotechnology
    • Clinical Trials
    • Innovation

    New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?

    Read

    Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST

    BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk

    • Biotechnology
    • Biotech
    • Pharma
    • biosimilars
    • patents

    The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.

    Read

    Commented by Carsten Mainitz on October 7th, 2026 | 08:40 CEST

    Spot the Next Stock Catalyst Early: Key Milestones for Lahontan Gold, Evotec and Deutz

    • Mining
    • Gold
    • Silver
    • Commodities
    • Defense
    • geopolitics
    • Biotech

    Get in before the stock takes off! The key is to identify the trigger for the next share-price move early enough. Lahontan Gold is working to restart a historic gold mine in Nevada and recently made an attractive acquisition. Biotech company Evotec is fighting to turn its operations around and rebuild investor confidence. Deutz is expanding its industrial business into energy and defense, taking the company into new dimensions of growth. What does this mean for investors? Where are the most compelling opportunities for stock pickers?

    Read